Print

Biostar Pharmaceuticals, Inc. (BSPM) Commences Call Center Operations  
12/21/2012 8:37:56 AM

XIANYANG, China, Dec. 21, 2012 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its call center commenced operations on December 10, 2012.

Earlier this year, the Company established a call center in Xianyang as its new business-to-customer ("B2C") sales platform. The Company has staffed the call center with 14 professionally trained sales employees (8 operators and 6 sales agents) that are primarily responsible for incoming inquiries and orders. The staff is also responsible for informing customers about drug promotions, introducing customers to new drugs, gathering customer feedback, and, if so requested, connecting them with doctors for further consultation. Additionally, the call center sales personnel is responsible for outreach activities, including contacting medical product distribution agencies throughout China about product promotions, signing new distribution agreements and negotiating renewals.

The B2C call center is currently promoting sales of Biostar products that treat joint pain, kidney ailments, rhinitis, and digestion problems.

Ronghua Wang, Biostar's Chief Executive Officer and Chairman, commented, "Since the call center became operational, our staff has been handling over 300 customer calls daily and has booked sales of between RMB50,000 - RMB80,000 (approximately $8,000 - $13,000) daily."

Mr. Wang continued, "We are confident that the services we are offering through our B2C sales platform will further enhance customer confidence in and loyalty to our products, and will provide an additional boost to the Company's sales efforts going forward. Our goal is to gradually increase daily sales volume and ultimately achieve approximately $5 million in 2013 revenues from the sale of products through our call center."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the Company's ability to recover its sales and revenue for the gel capsule segment of its business, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




Biostar Pharmaceuticals, Inc.

The Equity Group, Inc.

Ally Gong

Lena Cati

Tel: 011 86 29 3368-6638

Tel: 212 836-9611

Email: office@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.


//-->